Relay Therapeutics
RLAY
199 hedge funds and large institutions have $867M invested in Relay Therapeutics in 2025 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 63 increasing their positions, 63 reducing their positions, and 26 closing their positions.
2,019% more call options, than puts
Call options by funds: $3.98M | Put options by funds: $188K
47% more capital invested
Capital invested by funds: $592M → $867M (+$276M)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
0% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 63
3.34% less ownership
Funds ownership: 99.71% → 96.38% (-3.3%)
4% less funds holding
Funds holding: 208 → 199 (-9)
23% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Commodore Capital
New York
|
+$13.9M |
| 2 |
TCM
TCG Crossover Management
Palo Alto,
California
|
+$6.9M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$5.06M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
+$4.48M |
| 5 |
Morgan Stanley
New York
|
+$1.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$14.8M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$6.63M |
| 3 |
Millennium Management
New York
|
-$4.29M |
| 4 |
AG
Algert Global
San Francisco,
California
|
-$2.26M |
| 5 |
Renaissance Technologies
New York
|
-$1.85M |
RLAY Hedge Fund Activity: Q3 2025 in Review
199 of the 7,641 institutional investors tracked by Wall St. Rank reported a position in Relay Therapeutics (RLAY) for Q3 2025, worth a combined $867M — up 47% from $592M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of RLAY and 20 opened new positions — a net loss of 6 holders — while 63 trimmed existing stakes and 63 added.
The largest buyer was Commodore Capital, adding an estimated $13.9M. The largest seller was JP Morgan Chase, cutting an estimated $14.8M.
- 199 institutional investors held Relay Therapeutics (RLAY) as of Q3 2025, down from 208 in Q2 2025.
- Funds reported $867M of Relay Therapeutics stock for Q3 2025, up 47% quarter-over-quarter.
- 20 funds opened new Relay Therapeutics positions in Q3 2025 and 26 closed out, a net change of -6 holders.
- The largest Relay Therapeutics buyer in Q3 2025 was Commodore Capital, an estimated $13.9M added.
- The largest Relay Therapeutics seller in Q3 2025 was JP Morgan Chase, an estimated $14.8M sold.
Based on aggregated 13F filings for Q3 2025.